PreveCeutical Medical Inc

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel.

Parekh telling proactive the next step they are undertaking with human tissue. He also talked about the progress made in screening peptides isolated from Caribbean Blue Scorpion venom to help combat some of the most aggressive diseases where there exists unmet clinical need, such as cancer.

Quick facts: PreveCeutical Medical Inc

Price: $0.04

Market: CSE
Market Cap: $15.86 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...



PreveCeutical Medical provides update on development of Sol Gel technology

PreveCeutical Medical (CSE:PREV) Chief Science Officer Mak Jawadeker joined Steve Darling from Proactive Investors Vancouver on Skype to give an update on their Sol Gel Technology. That technology being a drug delivery device. Jawadeker telling Proactive they are working on the patents...

on 1/2/19

2 min read